Skip to main content

Advertisement

Log in

Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Aim

To investigate the role of human epididymis protein 4 (HE4) in the diagnosis and prognosis of patients with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent chemoradiotherapy (CRT).

Methods

A total of 218 patients with LA-NSCLC were enrolled. All patients underwent CRT. The treatment response to CRT was evaluated. The prognosis analysis was performed using relapse-free survival (RFS) and overall survival [1].

Results

Our data show that the serum HE4 can discriminate patients who respond well to CRT from those who respond poorly. Higher serum HE4 had dramatically increased risk of being non-responders to CRT. Serum HE4 level is also associated with prognosis of patients after CRT. Patients with high HE4 level had shorter RFS and OS compared to those with low HE4 level.

Conclusion

Our data suggest that serum HE4 may be a useful prognostic biomarker for LA-NSCLC patients who underwent CRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ordu C, Selcuk NA, Akosman C, Eren OO, Altunok EC, Toklu T, et al. Comparison of metabolic and anatomic response to chemotherapy based on PERCIST and RECIST in patients with advanced stage non-small cell lung cancer. Asian Pac J Cancer Prev. 2015;16:321–6.

    Article  PubMed  Google Scholar 

  2. Semrau S, Klautke G, Virchow JC, Kundt G, Fietkau R. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med. 2008;102:210–8.

    Article  CAS  PubMed  Google Scholar 

  3. Ratanatharathorn V, Lorvidhaya V, Kraipiboon P, Sirachainan E, Maoleekoonpairoj S, Phromratanapongse P, et al. Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report. J Med Assoc Thai. 2000;83:85–92.

    CAS  PubMed  Google Scholar 

  4. Jett JR, Schild SE, Keith RL, Kesler KA. American College of Chest P: treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:266S–76S.

    Article  PubMed  Google Scholar 

  5. Manolov V, Marinov B, Vasilev V, Andreeva A. HE4—a new tumor marker for ovarian cancer. Akush Ginekol (Sofiia). 2011;50(Suppl 2):11–5.

    Google Scholar 

  6. Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, et al. HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem. 2011;55:1–20.

    Article  CAS  PubMed  Google Scholar 

  7. Wang X, Fan Y, Wang J, Wang H, Liu W. Evaluating the expression and diagnostic value of human epididymis protein 4 (HE4) in small cell lung cancer. Tumour Biol. 2014;35:6847–53.

    Article  CAS  PubMed  Google Scholar 

  8. Stiekema A, Boldingh QJ, Korse CM, van der Noort V, Boot H, van Driel WJ, et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecol Oncol. 2015;136:562–6.

    Article  CAS  PubMed  Google Scholar 

  9. Nagy B Jr, Bhattoa HP, Steiber Z, Csoban M, Szilasi M, Mehes G, et al. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer. Clin Chem Lab Med. 2014;52:1639–48.

    Article  CAS  PubMed  Google Scholar 

  10. Lamy PJ, Plassot C, Pujol JL. Serum HE4: an independent prognostic factor in non-small cell lung cancer. PLoS One. 2015;10:e0128836.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012;50:2181–8.

    Article  CAS  PubMed  Google Scholar 

  12. Choi JE, Villarreal J, Lasala J, Gottumukkala V, Mehran RJ, Rice D, et al. Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study. Cancer Med. 2015;4:825–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Jiang Y, Wang C, Lv B, Ma G, Wang L. Expression level of serum human epididymis 4 and its prognostic significance in human non-small cell lung cancer. Int J Clin Exp Med. 2014;7:5568–72.

    PubMed  PubMed Central  Google Scholar 

  14. Liu W, Yang J, Chi PD, Zheng X, Dai SQ, Chen H, et al. Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis. Int J Tuberc Lung Dis. 2013;17:1346–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a grant from the Binzhou Medical University (BY-121).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Y.-Z. Hao.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lan, WG., Hao, YZ., Xu, DH. et al. Serum human epididymis protein 4 is associated with the treatment response of concurrent chemoradiotherapy and prognosis in patients with locally advanced non-small cell lung cancer. Clin Transl Oncol 18, 375–380 (2016). https://doi.org/10.1007/s12094-015-1375-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1375-y

Keywords

Navigation